Retina

The second and third required PPQ batches are scheduled, and should they meet specifications, the new TRIESENCE production process will be complete, allowing Harrow to relaunch during 2024.

The role of calendars may be growing more important when managing patients with nAMD and DME. How many weeks can patients go between injections with newer anti-VEGF agents versus older options? How short of an injection interval can patients tolerate before it becomes too much of a burden? In this podcast, Murtaza Adam, MD; Laxmi Devisetty, MD, Hong-Uyen Hua, MD; and Sherrol Reynolds, OD; share insights into determining appropriate treatment regimens with these therapies and supporting patient adherence.

A priority review has been granted with a PDUFA goal date set for December 17, 2024.

The company highlighted successful enrollment in the SOL-1 Phase 3 trial for wet AMD, plans for a new repeat dosing study (SOL-R), and positive 48-week data from the Phase 1 HELIOS study for NPDR

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Researchers examined data of more than 200,000 people, some at an early stage of the disease and some without age-related eyesight issues

Authors pointed out that understanding this link may aid with genetic counseling or surveillance of affected individuals, potentially contributing to improved management and outcomes.

According to researchers at Waseda University in Japan, the proposed device can measure electrical potentials from different places in the retina simultaneously, which is useful in diagnosing eye diseases.

McDonnell stays focused on helping the next generation of ophthalmologists launch their careers in academics.

Prevent Blindness provides free resources on Stargardt disease, including a webpage, fact sheets, expert interview video and social media graphics, to educate the public and professionals on the inherited retinal disease.

Researchers note the G90D mutation in rhodopsin is known to produce background electrical noise to desensitize rods, but the nature of the ‘noise’ and its precise molecular source have not been resolved for almost 30 years.

The trial evaluates OCU410ST, a modifier gene therapy candidate utilizing an AAV delivery platform for the retinal delivery of the RORA gene.

Researchers at the University of Missouri School of Medicine have conducted a study in a humanized mouse model to show that infections can occur deep inside the eye by penetrating the blood-retinal barrier.

GLOW2 follows the GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in ≥ 2-step improvement in DRSS and 89% decreased risk of developing sight-threatening complications.

Researchers at Massachusetts Eye and Ear led a phase 1/2 trial, which included 14 participants, that found the experimental treatment was safe and efficacious.

Noha A. Sherif, MD, and Sandra Hoyek, MD, conducted a retrospective chart review to identify the clinical characteristics of the injured eyes that may be associated with visual recovery in this patient population.

While it fell short of the primary endpoint of improvement of non-proliferative diabetic retinopathy (NPDR) of at least 2 Diabetic Retinopathy Severity Scale (DRSS) levels as of week 36, DURAVYU did demonstrate stable or improved disease severity with reduced rates of NPDR in 9 months.

An analysis showed an association between patients who previously had undergone intravitreal injections and cataract surgery and a higher risk of the development of a non-clearing vitreous hemorrhage, retinal detachment, retinal tear, and glaucoma surgery.

Voretigene neparvovec (Luxturna, Spark Therapeutics, Inc.) was shown to be safe and effective in real-world settings.

Tylectomy indicates surgical resection of retinoblastomas via pars plana vitrectomy with intraoperative chemotherapy infusion.

The 18th annual Controversies in Modern Eye Care conference, held on May 4, 2024, in Los Angeles, was co-chaired by Neda Shamie, MD, and Arjan Hura, MD, with the aim of discussing the latest advancements in eye care.

Hura highlighted some of the key takeaways from the Controversies in Modern Eye Care symposium where presenters and attendees shared their insights into the latest advancements in refractive surgery, retina care, and collaborative eye care.

According to the company, a subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in 2 patients. Safety data from the first cohort of the LIGHTHOUSE study will be presented at the Retinal Cell and Gene Therapy Innovation Summit 2024 being held May 3, 2024, in Seattle.